Lipitor generic availability?

Lipitor generic availability

The generic version of Lipitor became available in the United States in November 2011 when Pfizer’s main patent expired. Since then, several manufacturers have offered atorvastatin calcium tablets in the same strengths as the brand-name product.

How long did exclusivity last?

Pfizer held both composition-of-matter and method-of-use patents that delayed generic entry until the final court rulings cleared the way in late 2011. Once the primary patent fell, FDA approvals moved quickly and multiple generics launched on the same day.

Why are companies challenging this patent?

Before launch, generic firms filed paragraph IV certifications against Pfizer’s remaining patents. Courts invalidated several of those claims, which opened the market. Ongoing litigation now focuses on narrower formulation and dosing patents that have little effect on current generic supply.

Can biosimilars enter before patent expiry?

Atorvastatin is a small-molecule drug, so biosimilar rules do not apply. Generic small-molecule versions were able to launch once the compound patent and regulatory exclusivities ended.

What side effects are patients asking about?

Common questions involve muscle pain, elevated liver enzymes, and potential drug interactions with certain antibiotics and antifungals. These concerns are the same for brand and generic atorvastatin.

How does this drug compare with other statins?

Atorvastatin remains one of the most potent statins on a milligram-per-milligram basis and is widely used for lowering LDL cholesterol. Generic availability has lowered its cost significantly compared with branded alternatives still under patent.

Who makes the generic?

Major suppliers include Teva, Mylan (now part of Viatris), Sandoz, and several Indian manufacturers. Prices vary by strength and quantity, but the drug is now among the least expensive statins on most formularies.

When does the next patent expire?

Pfizer’s remaining U.S. patents on specific formulations and pediatric dosing expired by 2015. No further composition patents block additional generic competition.

DrugPatentWatch.com